Vivani Medical (NASDAQ:VANI – Get Free Report) announced its quarterly earnings results on Wednesday. The company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.01, Zacks reports.
Vivani Medical Trading Down 8.5%
VANI traded down $0.08 on Friday, reaching $0.90. The company had a trading volume of 59,860 shares, compared to its average volume of 321,746. The company has a market capitalization of $81.18 million, a P/E ratio of -2.81 and a beta of 2.51. The company has a fifty day moving average of $1.19 and a 200-day moving average of $1.24. Vivani Medical has a one year low of $0.80 and a one year high of $1.66.
Analyst Ratings Changes
A number of research analysts have weighed in on VANI shares. Wall Street Zen downgraded Vivani Medical from a “hold” rating to a “sell” rating in a report on Saturday, November 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Vivani Medical in a report on Friday, October 2nd. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $3.75.
View Our Latest Analysis on Vivani Medical
Vivani Medical Company Profile
Vivani Medical is a clinical-stage medical technology company developing miniature, implantable devices designed to deliver medicines over extended periods. Its NanoPortal platform is intended to provide sustained drug delivery from a small implant placed under the skin, with the goal of reducing the need for frequent dosing. The company is advancing implant programs based on GLP-1 medicines for chronic conditions, including obesity and type 2 diabetes. These programs remain in development, and their availability and use depend on clinical and regulatory progress.
Featured Stories
- Five stocks we like better than Vivani Medical
- Costco’s Record $30 Dividend Shows Just How Strong Its Cash Machine Is
- Heavy Lifting: Can USA Rare Earth Turn Its First Sales Into Big Profits?
- These 3 Stocks Have Bought Back Billions, But Which Offers the Best Value?
- Golden Dome’s $185 Billion Question: Who Actually Gets Paid?
Receive News & Ratings for Vivani Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivani Medical and related companies with MarketBeat.com's FREE daily email newsletter.
